Frontotemporal dementia and early Alzheimer disease: Differentiation with frontal lobe H-1 MR spectroscopy

Radiology

Volumn 203, Issue 3, 1997, Pages 829-836

  Ernst, Thomas ^a   Chang, Linda ^a   Melchor, Rosemarie ^a   Mark Mehringer, C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aging; Brain, gray matter; Brain, metabolism; Dementia; Magnetic resonance (MR), spectroscopy

Indexed keywords

GLUTAMIC ACID; GLUTAMINE; INOSITOL; LACTIC ACID; N ACETYLASPARTIC ACID;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN LEVEL; CELL LOSS; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DEMENTIA; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; FEMALE; FRONTAL LOBE; GLIA; HUMAN; MALE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; TEMPORAL LOBE;

EID: 0030915132     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiology.203.3.9169712     Document Type: Article

References (63)

1. Jagust WJ, Budinger TF, Reed BR. The diagnosis of dementia with single photon emission tomography. Arch Neurol 1987; 44:258-262.
2. Chang L, Yener GG, Miller BL, Mehringer M. Magnetic resonance spectroscopy and single photon emission computed tomography in Alzheimer's disease: new directions. Facts Res Gerontol 1994; 5:67-78.
3. Mazziotta JC, Frackowiak RSJ, Phelps ME. The use of positron emission tomography in the clinical assessment of dementia. Semin Nucl Med 1992; 12:233-246.
4. 18F scan in Alzheimer's disease and multi-infarcted dementia. Arch Neurol 1983; 40:711-714.
5. Snow BL. Positron emission tomography in Parkinson's disease. Neurol Sci 1992; 19:138-141.
6. Karbe H, Grond M, Huber M, Herholz K, Kesler J, Heiss WD. Subcortical damage and cortical dysfunction in progressive supranuclear palsy demonstrated by positron emission tomography. J Neurol 1992; 239: 98-102.
7. 18F-fluorodeoxyglucose method. Ann Neurol 1984; 15:419-424.
8. Bowen BC, Block RE, Sanchez-Ramos J, et al. Proton MR spectroscopy of the brain in 14 patients with Parkinson disease. AJNR 1995; 16:61-68.
9. Graham GD, Petroff OAC, Blamire AM, Rajkowska G, Goldman-Rakic P, Prichard JW. Proton magnetic resonance spectroscopy in Creutzfeldt-Jakob disease. Neurology 1993; 43:2065-2068.
10. Miller BL, Moats R, Shonk T, Ernst T, Wooley S, Ross BD. Alzheimer disease: depiction of increased cerebral myo-inositol with proton MR spectroscopy. Radiology 1993; 187:433-437.
11. Brun A. Frontal lobe degeneration of non-Alzheimer type. I. Neuropathology. Arch Gerontol Geriatr 1987; 6:193-208.
12. Neary D, Snowden JS, Northen B, Goulding P. Dementia of frontal lobe type. J Neurol Neurosurg Psychiatr 1988; 51:353-361.
13. Gustafson L. Clinical picture of frontal lobe degeneration of non-Alzheimer type. Dementia 1993; 4:143-148.
14. Neary D, Snowden JS, Mann DMA, Northen B, Goulding PJ, Macdermott N. Frontal lobe dementia and motor neuron disease. J Neurol Neurosurg Psychiatr 1990; 53: 23-32.
15. Dickson DW, Horoupian DS, Thal LJ, Davies P, Walkeley S, Terry RD. Kluver-Bucy syndrome and amyotrophic lateral sclerosis: a case report with biochemistry, morphometrics, and Golgi study. Neurology 1986; 36:1323-1329.
16. Chang L, Cornford M, Miller BL, Itabashi H, Mena I. Neuronal ultrastructural abnormalities in a patient with frontotemporal dementia and amyotrophic lateral sclerosis. Dementia 1995; 6:1-8.
17. Klatka LA, Schiffer RB, Powers JM, Kazee AM. Incorrect diagnosis of Alzheimer's disease. Arch Neurol 1996; 53:35-42.
18. Risberg J. Frontal lobe degeneration of non-Alzheimer type. III. Regional cerebral blood flow. Arch Gerontol Geriatr 1987; 6:225-233.
19. Caselli RJ, Jack CR, Petersen RC, Wahner HW, Yanagihara T. Asymmetric cortical degenerative syndromes: clinical and radiologic correlations. Neurology 1992; 42: 1462-1468.
20. Miller BL, Cummings JL, Villanueva-Meyer J, et al. Frontal lobe degeneration: clinical, neuropsychological and SPECT characteristics. Neurology 1991; 41:1374-1382.
21. Tyrell PJ, Warrington EK, Frackowiak RSJ, Rossor MN. Progressive degeneration of the right temporal lobe studied with positron emission tomography. J Neurol Neurosurg Psychiatr 1990; 53:1046-1050.
22. Brun A. Frontal lobe dementia of the non-Alzheimer type revisited. Dementia 1993; 4:126-131.
23. Pick A. Uber die beziehungen der senilen hirnatrophie zur aphasie. [On the relation between aphasia and senile atrophy of the brain.] In: Rottenberg DA, Hochberg FH, eds. Neurological classics in modern translation. New York, NY: Hafner, 1897; 35-40.
24. Knopman DS, Christensen KJ, Schut LJ, et al. The spectrum of imaging and neuropsychological findings in Pick's disease. Neurology 1989; 39:362-368.
25. Caselli R. Focal and asymmetric cortical degeneration syndromes. Neurologist 1995; 1:1-19.
26. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41: 479-486.
27. Bartus RT, Dean RL, Pontecorvo MJ, Flicker C. The cholinergic hypothesis: a historical overview, current perspective, and future directions. In: Olton D, Gamzu E, Corkin S, eds. Memory dysfunctions: integration of animal and human research from clinical and preclinical perspectives. New York, NY: New York Academy of Sciences, 1985; 332-358.
28. Sparks AD, Markesbery WR. Altered serotonergic and cholinergic markers in Pick's disease. Arch Neurol 1991; 48:796-799.
29. Edvinsson L, Mintho L, Ekman R, Gustafson L. Neuropeptides in cerebrospinal fluid of patients with Alzheimer's disease and dementia with frontotemporal lobe degeneration. Dementia 1993; 4:167-171.
30. 1H-NMR spectroscopic studies of brain. Neurosci Biobehav Rev 1989; 13:23-31.
31. Barker PB, Breiter SN, Soher BJ, et al. Quantitative proton spectroscopy of canine brain: in vivo and in vitro correlations. Magn Reson Med 1994; 32:157-163.
32. 1H spectroscopy: glutamate and glutamine; myo-inositol and related metabolites. NMR Biomed 1991; 4:59-63.
33. Moats R, Ernst T, Shonk T, Ross BD. Abnormal cerebral metabolite concentrations in patients with probable Alzheimer's disease. Magn Reson Med 1994; 32:110-115.
34. Shonk TK, Moats RA, Gifford P, et al. Probable Alzheimer disease: diagnosis with proton MR spectroscopy. Radiology 1995; 195: 65-72.
35. Christiansen P, Schlosser A, Henriksen O. Reduced N-acetylaspartate content in the frontal part of the brain in patients with probable Alzheimer's disease. Magn Reson Imaging 1995; 13:457-162.
36. Meyerhoff DJ, MacKay S, Constans JM, et al. Axonal injury and membrane alterations in Alzheimer's disease suggested by in vivo proton magnetic resonance spectroscopic imaging. Ann Neurol 1994; 36:40-47.
37. MacKay S, Ezekiel F, Di Sclafani V, et al. Alzheimer disease and subcortical ischemic vascular dementia: evaluation by combining MR imaging segmentation and H-1 MR spectroscopic imaging. Radiology 1996; 198:537-545.
38. The Lund and Manchester Groups. Consensus statement. J Neurol Neurosurg Psychiatr 1994; 57:416-118.
39. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34:939-944.
40. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198.
41. Hughes CP, Berg I, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychol 1982; 140:566-572.
42. Small GW, Okonek A, Mandelkern MA, et al. Age-associated memory loss: initial neuropsychological and cerebral metabolic findings of a longitudinal study. Int Psychogeriatr 1994; 6:23-44.
43. Davies PC, Gray L, Albert M, et al. The Consortium to Establish a Registry for Alzheimer Disease (CERAD). Neurology 1992; 42:1676-1680.
44. Small GW, Mazziotta JC, Collins MT, et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 1995; 273: 942-947.
45. Bottomley PA. Spatial localization in NMR spectroscopy in vivo. Ann NY Acad Sci 1987; 508:333-348.
46. 1H MR spectroscopy of the frontal lobe. Magn Reson Med 1996; 36:462-468.
47. Ernst T, Kreis R, Ross BD. Absolute quantitation of water and metabolites in the human brain. I. Compartments and water. J Magn Reson 1993; 102:1-8.
48. Kreis R, Ernst T, Ross BD. Absolute quantitation of water and metabolites in the human brain. II. Metabolite concentrations. J Magn Reson 1993; 102:9-19.
49. 1H NMR spectroscopy in patients with chronic hepatic encephalopathy: analysis of changes in cerebral glutamine, choline, and inositols. NMR Biomed 1991; 4:109-116.
50. Negendank W. Studies of human tumors by MRS: a review. NMR Biomed 1992; 5:303-324.
51. Chang L, Miller B, McBride D, et al. Brain lesions in patients with AIDS: H-1 MR spectroscopy. Radiology 1995; 197:527-531.
52. Gideon P, Henriksen O, Sperling B, et al. Early time course of N-acetylaspartate, creatine, and phosphocreatine, and compounds containing choline in the brain after acute stroke: a proton magnetic resonance spectroscopy study. Stroke 1992; 23:1566-1572.
53. Graham GD, Blamire AM, Rothman DL, et al. Early temporal variation of cerebral metabolites after human stroke: a proton magnetic resonance spectroscopy study. Stroke 1993; 24:1891-1896.
54. Arnold DL, Matthews PM, Francis G, Antel J. Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease. Magn Reson Med 1990; 14:157-163.
55. Carr CA, Guimaraes AR, Growdon JH, Gonzalez RG. Combining proton MRS and MRI morphometry increases accuracy in the diagnosis of Alzheimer's disease (abstr). In: Book of abstracts. International Society for Magnetic Resonance in Medicine 1993. New York, NY: International Society for Magnetic Resonance in Medicine, 1993; 233.
56. Shiino A, Matsuda M, Morikawa S, Inubushi T, Akiguchi I, Handa J. Proton magnetic resonance spectroscopy with dementia. Surg Neurol 1993; 39:143-147.
57. Yates CM, Butterworth H, Tennant MC, Gordon A. Enzyme activities in relation to pH and lactate in postmortem brain in Alzheimer-type and other dementias. J Neurochem 1990; 55:1624-1630.
58. Brand A, Richter-Landsberg C, Leibfritz D. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci 1993; 15:289-298.
59. Lien Y, Shapiro J, Chan L. Effects of hypernatremia on organic brain osmoles. J Clin Invest 1990; 85:1427-1435.
60. Kimelberg H, O'Connor EHK. Effects of swelling on glial cell function. In: Lang F, Haeussinger D, eds. Interactions in cell volume and cell function. Heidelberg, Germany: Springer-Verlag, 1993; 158-186.
61. Petroff OAC, Graham GD, Blamire AM, et al. Spectroscopic imaging of stroke in humans: histopathology correlates of spectral changes. Neurology 1992; 42:1349-1354.
62. Mathews PM, Andermann F, Silver K, Karparti G, Arnold DL. Proton MR spectroscopic characterization of differences in regional brain metabolic abnormalities in mitochondrial encephalomyopathies. Neurology 1993; 43:2484-2490.
63. Resnick SM, Costa PT. Comments on use of H-1 MR spectroscopy for diagnosis of probable Alzheimer disease (editorial). Radiology 1995; 195:14-15.